Maissaa Janbain
Hematology & Oncology · New Orleans, LANPI 1962668707
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Sanofi at 49.4% of the total. Among hematology & oncology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 599 payments — averaging $1438.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$426K
- CSL Behring$106K
- Takeda Pharmaceuticals U.S.A., Inc.$64K
- HEMA Biologics, LLC$44K
- Biomarin Pharmaceutical Inc.$43K
- Pfizer$36K
- plus $142K from 13 others
Across 123 payments — averaging $5076.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$159K
- Takeda Pharmaceuticals U.S.A., Inc.$88K
- Bayer$82K
- Pfizer$51K
- Sanofi$51K
- Biomarin Pharmaceutical Inc.$39K
- plus $155K from 10 others
What the payments were for
- Consulting fees$281,21333%
- Speaking & faculty fees$473,35855%
- Travel & lodging$92,72511%
- Food & beverage$14,1432%
- Education$1010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 214 | $425,795 |
| CSL Behring | 95 | $106,350 |
| Takeda Pharmaceuticals U.S.A., Inc. | 40 | $64,333 |
| HEMA Biologics, LLC | 39 | $44,280 |
| Biomarin Pharmaceutical Inc. | 43 | $42,675 |
| Pfizer | 25 | $36,277 |
| Genentech USA, Inc. | 35 | $32,592 |
| Sanofi-aventis U.S. LLC | 9 | $21,558 |
| Shire North American Group Inc | 31 | $19,893 |
| Swedish Orphan Biovitrum AB | 4 | $16,021 |
| Spark Therapeutics, Inc. | 12 | $13,496 |
| Sobi, Inc | 11 | $13,005 |
| Octapharma USA, Inc. | 22 | $9,423 |
| Bioverativ Therapeutics Inc. | 2 | $6,110 |
| Bayer | 8 | $4,040 |
| Novo Nordisk | 4 | $2,861 |
| Kedrion Biopharma Inc. | 1 | $2,679 |
| Regeneron | 1 | $91 |
| Novartis | 3 | $63 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALTUVIIIO$197,867
- HEMGENIX$82,068
- QFITLIA$46,130
- CABLIVI$44,477
- SevenFact$39,833
- HYMPAVZI$36,123
- HEMLIBRA$31,720
- ALPROLIX$25,519
- Idelvion$20,053
- ADVATE$19,846
- Roctavian$15,524
- DOPTELET$12,876
- VONVENDI$12,134
- WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN)$8,939
- Afstyla$8,523
- ADYNOVATE$6,987
- ELOCTATE$3,630
- FEIBA$2,900
- NovoSeven RT$2,720
- KOATE$2,679
How this compares
$861,540 in reported general payments places this provider in the 95th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tranexamic Acid | 14 | $4,662 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in New Orleans
- Pedro BarataNew Orleans$928K
- Marc MatranaNew Orleans$757K
- Lingling duNew Orleans$173K
- Cindy LeissingerNew Orleans$135K
- Carter DavisNew Orleans$61K
- Furhan YunusNew Orleans$55K
- Michelle LochNew Orleans$50K
- David MorrisonNew Orleans$23K
- Scott SonnierNew Orleans$20K
- Ralph MillettNew Orleans$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.